Back to search

National and Kapodistrian University of Athens

Μελέτη του τίτλου των αντισωμάτων σε άτομα με και χωρίς σακχαρώδη διαβήτη μετά από εμβολιασμό για τον SARS-COV-2

Abstract

dc:description

INTRODUCTION: Patients with diabetes mellitus (DM) are at increased risk of developing severe disease and death from COVID-19. Therefore, vaccination of people with DM against SARS-CoV-2 is mandatory. Hyperglycemia has been shown to impair multiple aspects of innate and adaptive immunity contributing to increased susceptibility to infections in patients with DM and uncontrolled hyperglycemia. Whether hyperglycemia affects the humoral response after vaccination is unknown. PURPOSE: The aim of this study was to examine humoral immune response in participants with and without DM after vaccination with BNT162b2 mRNA vaccine. Antibodies were measured in serum by an anti-SARS-CoV-2-RBD IgG assay (Abbott SARS-CoV-2 IgG II Quant); it quantifies IgG antibodies against the receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 by a chemiluminescent microparticle immune assay. Values > 50 AU/mL are considered protective from severe disease. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, 100-110 days and 180-200 days from the first dose and 180-200 days after the 3rd booster dose. METHODOLOGY: 171 individuals participated in the study, of whom 62 had a history of DM (49 had type 2 DM and 13 had type 1 DM) and 109 did not (control group). Thereafter, 62 participants from the control group were matched based on gender, age, height and weight with 62 individuals with DM (matched population). The individuals with DM had a mean age of 55,1±12,83 years and a mean body mass index of 29,73±4,80 kg/m2. The mean duration of DM was 15 years and the mean HbA1c was 7%. RESULTS: Αfter the 1st dose of the vaccine, 21% of individuals with DM did not develop protective antibodies compared to 5% of individuals from the control group (p = 0.014). Morover, the antibody titer was significantly lower in individuals with DM compared to the control group (p = 0.010) after the administration of a single dose of the vaccine. This diminished response in individuals with DM was eliminated by the administration of the second dose of the vaccine and 7-15 days later all patients with DM had detectable neutralizing IgG antibodies. At 3 months and 6 months after the first dose of the vaccine, a significant decrease in antibody titer was observed in all participants. The antibody titer in individuals with DM was lower at 3 and 6 months after the first dose than in the control group. All participants received a 3rd booster dose at least 3 months after the second dose. Meanwhile, 42 individuals (38.5%) without DM and 23 (37.1%) people with DM self-reported COVID-19 infecton, most of them 6-8 months after the second dose of the vaccine. Six months after the third booster dose, the antibody titer in individuals with DM did not differ from that in the control group.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadokostaki, Eleni
  • Παπαδοκωστάκη, Ελένη

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/59900

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadokostaki, Eleni; Παπαδοκωστάκη, Ελένη. Μελέτη του τίτλου των αντισωμάτων σε άτομα με και χωρίς σακχαρώδη διαβήτη μετά από εμβολιασμό για τον SARS-COV-2. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/59900